Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

NCT02855359 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision based on portfolio prioritization

Conditions

Diffuse, Large B-Cell, Lymphoma
Follicular Lymphoma, Grade 3b
Transformed Lymphoma / DLBCL

Interventions

DRUG: denintuzumab mafodotin
DRUG: rituximab
DRUG: cyclophosphamide
DRUG: doxorubicin
DRUG: vincristine
DRUG: prednisone

Sponsor

Seagen Inc.